Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial - Dena Battle

President of KCCure, Dena Battle joins Monty Pal in a discussion on the management of de novo metastatic kidney cancer and the change in practice from cytoreductive nephrectomy to an option of systemic therapy driven by the results of CARMENA trial. Dena shares the patients perspective on this treatment paradigm which comes from a patient survey her organization put forth answering the question of if patients would still prefer upfront surgery before starting systemic treatment knowing first and foremost that surgery would not impact overall survival. An interestingly high number, Dena advocates for the importance to patients in understanding the complexity of studies like the CARMENA trial.


Dena Battle is the President for KCCure. She began her career in Washington, DC, as a congressional aide, and went on to work as a lobbyist for more than 10 years, working primarily on tax and healthcare policy. She serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council. She has testified before the FDA – Oncological Drug Advisory Board (ODAC) and helped co-author an NCI-ASCO-sponsored paper on improving end-of-life care for cancer patients. In 2009, at the age of 40, Dena’s late husband Chris was diagnosed with metastatic kidney cancer. Together, they began a quest for the best care possible to combat the disease. Chris was treated at four different comprehensive cancer centers and participated in multiple clinical trials.

Sumanta Kumar Pal, MD Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, Medical Oncologist, City of Hope

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.